SERPINE1 rs6092 Variant Is Related to Plasma Coagulation Proteins in Patients with Severe COVID-19 from a Tertiary Care Hospital
Ingrid Fricke-Galindo, Ivette Buendía-Roldán, Leslie Chávez‐Galán, Gloría Pérez-Rubio, Rafael de Jesús Hernández-Zenteno, Espiridión Ramos-Martı́nez, Armando Zazueta-Márquez, Felipe Reyes-Melendres, Aimé Alarcón-Dionet, Javier Guzmán-Vargas, Omar Andrés Bravo-Gutiérrez, Teresa Quintero-Puerta, Ilse Adriana Gutiérrez-Pérez, Alejandro Ortega-Martínez, Enrique Ambrocio-Ortiz, Karol J. Nava-Quiroz, José Luis Bañuelos-Flores, María Esther Jaime-Capetillo, Mayra Mejía, Jorge Rojas‐Serrano, Ramcés Falfán‐Valencia
Abstract
An impaired coagulation process has been described in patients with severe or critical coronavirus disease (COVID-19). Nevertheless, the implication of coagulation-related genes has not been explored. We aimed to evaluate the impact of F5 rs6025 and SERPINE1 rs6092 on invasive mechanical ventilation (IMV) requirement and the levels of coagulation proteins among patients with severe COVID-19. Four-hundred fifty-five patients with severe COVID-19 were genotyped using TaqMan assays. Coagulation-related proteins (P-Selectin, D-dimer, P-selectin glycoprotein ligand-1, tissue plasminogen activator [tPA], plasminogen activator inhibitor-1, and Factor IX) were assessed by cytometric bead arrays in one- and two-time determinations. Accordingly, SERPINE1 rs6092, P-Selectin (GG 385 pg/mL vs. AG+AA 632 pg/mL, p = 0.0037), and tPA (GG 1858 pg/mL vs. AG+AA 2546 pg/mL, p = 0.0284) levels were different. Patients carrying the CT F5-rs6025 genotype exhibited lower levels of factor IX (CC 17,136 pg/mL vs. CT 10,247 pg/mL, p = 0.0355). Coagulation proteins were also different among IMV patients than non-IMV. PSGL-1 levels were significantly increased in the late stage of COVID-19 (>10 days). The frequencies of F5 rs6025 and SERPINE1 rs6092 variants were not different among IMV and non-IMV. The SERPINE1 rs6092 variant is related to the impaired coagulation process in patients with COVID-19 severe.